Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

921. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. (Abstract)

Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Few studies have examined the relationship between cigarette smoking and novel risk factors for cardiovascular disease in a general population or have included a biochemical marker of current smoking.To examine the relationship between cigarette smoking and serum C-reactive protein, fibrinogen, and homocysteine levels.Cross-sectional study.The U.S. general population.4187 current (...) smokers, 4791 former smokers, and 8375 never-smokers 18 years of age or older who participated in the Third National Health and Nutrition Examination Survey conducted between 1988 and 1994.Serum C-reactive protein levels were categorized as detectable (2.2 to 9.9 mg/L) or clinically elevated (> or =10 mg/L), and fibrinogen and homocysteine levels were defined as elevated if in the 85th percentile or greater (11.1 micromol/L and 12.7 mmol/L, respectively).After adjustment for traditional cardiovascular

2003 Annals of Internal Medicine

922. Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. (Abstract)

Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Kawasaki disease is an acute vasculitis of possible infectious cause, which in particular affects the coronary arteries. Young children rely mostly on their innate immune system for protection against invading microorganisms, of which mannose-binding lectin is an important component. We aimed to investigate the possible role of the gene for this molecule (MBL) in white Dutch patients (...) with Kawasaki disease. In 90 patients, frequency of mutations in the MBL gene was higher than in healthy children. In children younger than 1 year, those with mutations were at higher risk of development of coronary artery lesions than were those without (odds ratio 15.7, 95% CI 1.4-176.5, p=0.026). Our findings suggest that the innate immune system contributes differently to pathophysiology of Kawasaki disease at various ages.

2003 Lancet

923. Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals. Full Text available with Trip Pro

Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals. People older than 65 years are the fastest-growing segment of the population and account for the majority of cardiovascular disease (CVD) morbidity, mortality, and health care expenditures. Additionally, the influence of dietary habits on risk may be less pronounced in elderly persons, when atherosclerosis is more advanced. However, few data address the influence of diet on CVD risk (...) CVD (combined stroke, ischemic heart disease death, and nonfatal myocardial infarction).During 8.6 years mean follow-up, there were 811 incident CVD events. After adjustment for age, sex, education, diabetes, ever smoking, pack-years of smoking, daily physical activity, exercise intensity, alcohol intake, and fruit and vegetable fiber consumption, cereal fiber consumption was inversely associated with incident CVD (P for trend =.02), with 21% lower risk (hazard ratio [HR], 0.79; 95% confidence

2003 JAMA

924. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. Full Text available with Trip Pro

Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. Formation of nitric oxide-derived oxidants may serve as a mechanism linking inflammation to development of atherosclerosis. Nitrotyrosine, a specific marker for protein modification by nitric oxide-derived oxidants, is enriched in human atherosclerotic lesions and low-density lipoprotein (LDL) recovered from human atheroma.To determine whether systemic levels of nitrotyrosine are associated (...) with the prevalence of coronary artery disease (CAD) and are modulated by hydroxymethylglutaryl coenzyme-A reductase inhibitor (statin) therapy.A case-control and interventional study at 2 urban tertiary-care referral centers; recruitment for each was from June 1, 2001, until January 1, 2002. For the case-control study, 100 case-patients with established CAD and 108 patients with no clinically evident CAD were recruited consecutively. In the interventional study, participants aged 21 years or older

2003 JAMA

925. Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia. Full Text available with Trip Pro

Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia. To test the hypothesis that the incidence of fatal coronary heart disease and cardiovascular disease in a general population is related to serum and red cell folate and vitamin B-12 concentrations.Cohort study with follow up of 29 years.Busselton, Western Australia.1419 men and 1531 women aged 20 to 90 years, who were alive more than three years after their participation in the 1969 (...) Busselton health survey. 2314 (78.4%) had no cardiovascular disease at the initial survey.Hazard ratios for fatal coronary heart disease and cardiovascular disease in men and women according to baseline concentrations of serum and red cell folate and serum vitamin B-12.213 men and 159 women died from coronary heart disease, and 342 men and 302 women died from cardiovascular disease. Serum and red cell folate concentrations showed a moderate positive correlation (r=0.26, P<0.001) but otherwise serum

2003 BMJ

926. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease

compo- nent of the metabolic syndrome. 25 In several studies, base- line levels in the upper quartile of the population distri- bution in people without cardiovascular disease were associated with a 3- to 4-fold increased incidence of subse- quent coronary events. 24,26,27 Available data also suggest that measurement of the high-sensitivity C-reactive protein level may help target treatment to the population at risk; 28 this is relevant, since about half of all coronary events occur in people (...) , the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107(3):391-7. 26. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relationship of C-reactive pro- tein and coronary heart disease in the MRFIT nested case–control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144(6):537-47. 27. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C- reactive protein, a sensitive marker

2003 CPG Infobase

927. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk

Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk (...) . Source of effectiveness data The effectiveness data were derived from a review of the literature. Modelling A model was constructed to combine the costs and effectiveness for each intervention. A standard multi-state modelling tool, PopMod, was used to translate changes in the risk of cardiovascular disease events, specific for age and gender, into changes in population health quantified by disability-adjusted life-years (DALYs). PopMod simulates the evolution, with and without each intervention

2003 NHS Economic Evaluation Database.

928. Effects of statins on nonlipid serum markers associated with cardiovascular disease

Effects of statins on nonlipid serum markers associated with cardiovascular disease Effects of statins on nonlipid serum markers associated with cardiovascular disease Effects of statins on nonlipid serum markers associated with cardiovascular disease Balk E M, Lau J, Goudas L C, Jordan H S, Kupelnick B, Kim L U, Karas R H CRD summary This review assessed the effects of statins on nonlipid serum markers associated with cardiovascular disease. Of the nonlipid serum markers examined, only levels (...) criteria for the participants were given, other than that those who had undergone organ transplantation were excluded. In the included placebo-controlled studies, most of the participants had hyperlipidaemia; some also had diabetes, cardiovascular disease, end-stage renal disease, or a recent myocardial infarction. Outcomes assessed in the review The outcomes were reported as class effect (i.e. effect of any statin), as well as the effects of particular statins and comparisons between statins. Studies

2003 DARE.

929. An update on aspirin in the primary prevention of cardiovascular disease

An update on aspirin in the primary prevention of cardiovascular disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

930. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

931. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy (...) for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Blake G J, Ridker P M, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This paper examined the use of screening for C-reactive protein

2003 NHS Economic Evaluation Database.

932. Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations

exercise, lower fat diets, smoking cessation, and blood pressure assessment and control. There is insufficient evidence to make a recommendation on the use of HRT for the primary prevention of stroke and death from cerebrovascular disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cardiovascular Diseases /prevention & Cerebrovascular Disorders /prevention & Female; Hormone Replacement Therapy; Women's Health; control; control Language Published English Country (...) Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Abramson B L, with The Canadian

2003 Health Technology Assessment (HTA) Database.

933. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease

disease. Authors' conclusions For the combinations and conditions studied, the pooled analysis of smaller studies does not show evidence of an effect of vitamin E alone or in combination with other agents on all-cause mortality, cardiovascular mortality, fatal or nonfatal MI, or blood lipid levels. Results from a number of large clinical trials not included in the pooled analysis were substantially in agreement with this conclusion. Large studies of vitamin C in combination with other antioxidants (...) Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Shekelle P, Morton S, Hardy M Record Status This is a bibliographic record of a published health

2003 Health Technology Assessment (HTA) Database.

934. Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders

Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(12). 2003 Authors

2003 Health Technology Assessment (HTA) Database.

935. The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations

The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations Alkhenizan A, Palda V A, and the Canadian Task Force on Preventive Health Care Record Status (...) This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alkhenizan A, Palda V A, and the Canadian Task Force on Preventive Health Care. The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations. London, Ontario: Canadian Task Force on Preventive Health Care (CTFPHC) 2003: 36 Authors' objectives This report aims to establish evidence

2003 Health Technology Assessment (HTA) Database.

936. Routine vitamin supplementation to prevent cardiovascular disease

Routine vitamin supplementation to prevent cardiovascular disease Routine vitamin supplementation to prevent cardiovascular disease Routine vitamin supplementation to prevent cardiovascular disease Morris C D, Carson S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Morris C D, Carson S. Routine vitamin supplementation to prevent (...) cardiovascular disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic Evidence Review. 2003 Authors' objectives This study aims to assess the evidence on the effectiveness of routine vitamin supplementation to prevent cardiovascular disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cardiovascular Diseases /prevention & Dietary Supplements; Vitamins; control Language Published English Country of organisation United States

2003 Health Technology Assessment (HTA) Database.

937. Biochemical markers of cardiovascular disease risk

and serves as a guide for statin therapy in a primary prevention context. C-reactive protein (CRP), if measured by high-sensitivity assay (hs-CRP), may have independent value as a predictor of cardiovascular disease risk and independent value in identifying patients with normal lipids who could benefit from treatment (Conclusion Grade II). hs-CRP elevations can be caused by inflammatory conditions and, therefore, are not specific for cardiovascular assessment in individual patients. Further study (...) Biochemical markers of cardiovascular disease risk Biochemical markers of cardiovascular disease risk Biochemical markers of cardiovascular disease risk Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement. Biochemical markers of cardiovascular disease risk. Bloomington MN

2003 Health Technology Assessment (HTA) Database.

938. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. Full Text available with Trip Pro

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.The primary end point of this open, parallel trial was a composite of death from (...) cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin.The mean age

2003 NEJM Controlled trial quality: uncertain

939. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Full Text available with Trip Pro

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. The worldwide explosive increase in type 2 diabetes mellitus and its cardiovascular morbidity are becoming major health concerns.To evaluate the effect of decreasing postprandial hyperglycemia with acarbose, an alpha-glucosidase inhibitor, on the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance (IGT (...) and body mass index of 30.9 (4.2). These patients were followed up for a mean (SD) of 3.3 (1.2) years.Patients with IGT were randomized to receive either placebo (n = 715) or 100 mg of acarbose 3 times a day (n = 714).The development of major cardiovascular events (coronary heart disease, cardiovascular death, congestive heart failure, cerebrovascular event, and peripheral vascular disease) and hypertension (> or =140/90 mm Hg).Three hundred forty-one patients (24%) discontinued their participation

2003 JAMA Controlled trial quality: predicted high

940. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). (Abstract)

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population (...) consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated.Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease.

2003 Lancet Controlled trial quality: predicted high